Long-lasting response to lorlatinib in patients with ALK-driven relapsed or refractory neuroblastoma monitored with circulating tumor DNA analysis

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Cancer Research Communications

Topics

Biology

Cancer Oncology

Medicine

Internal Medicine

Neurology

Show all topics

DOI

10.1158/2767-9764.crc-24-0338

License

CC-BY

Other Formats

PDF